WallStSmart

BeyondSpring Inc (BYSI)vsVertex Pharmaceuticals Inc (VRTX)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Vertex Pharmaceuticals Inc generates 690284% more annual revenue ($12.95B vs $1.88M). VRTX leads profitability with a 30.7% profit margin vs 0.0%. VRTX earns a higher WallStSmart Score of 58/100 (C).

BYSI

Avoid

20

out of 100

Grade: F

Growth: 5.0Profit: 3.0Value: 6.7Quality: 4.5
Piotroski: 2/9Altman Z: -22.81

VRTX

Buy

58

out of 100

Grade: C

Growth: 5.3Profit: 9.0Value: 6.0Quality: 8.0
Piotroski: 4/9Altman Z: 3.69
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BYSIUndervalued (+89.1%)

Margin of Safety

+89.1%

Fair Value

$13.03

Current Price

$0.33

$12.70 discount

UndervaluedFair: $13.03Overvalued
VRTXUndervalued (+46.6%)

Margin of Safety

+46.6%

Fair Value

$974.60

Current Price

$515.02

$459.58 discount

UndervaluedFair: $974.60Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BYSI1 strengths · Avg: 10.0/10
Debt/EquityHealth
-0.0010/10

Conservative balance sheet, low leverage

VRTX4 strengths · Avg: 9.8/10
Profit MarginProfitability
30.7%10/10

Keeps 31 of every $100 in revenue as profit

Operating MarginProfitability
37.8%10/10

Strong operational efficiency at 37.8%

Altman Z-ScoreHealth
3.6910/10

Safe zone — low bankruptcy risk

Market CapQuality
$137.57B9/10

Large-cap with strong market position

Areas to Watch

BYSI4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$26.47M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

VRTX3 concerns · Avg: 3.3/10
PEG RatioValuation
2.384/10

Expensive relative to growth rate

P/E RatioValuation
34.9x4/10

Premium valuation, high expectations priced in

EPS GrowthGrowth
-39.0%2/10

Earnings declined 39.0%

Comparative Analysis Report

WallStSmart Research

Bull Case : BYSI

The strongest argument for BYSI centers on Debt/Equity. Revenue growth of 14.3% demonstrates continued momentum.

Bull Case : VRTX

The strongest argument for VRTX centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 30.7% and operating margin at 37.8%. Revenue growth of 11.8% demonstrates continued momentum.

Bear Case : BYSI

The primary concerns for BYSI are EPS Growth, Market Cap, Profit Margin.

Bear Case : VRTX

The primary concerns for VRTX are PEG Ratio, P/E Ratio, EPS Growth.

Key Dynamics to Monitor

BYSI profiles as a value stock while VRTX is a mature play — different risk/reward profiles.

VRTX carries more volatility with a beta of 0.28 — expect wider price swings.

BYSI is growing revenue faster at 14.3% — sustainability is the question.

VRTX generates stronger free cash flow (546M), providing more financial flexibility.

Bottom Line

VRTX scores higher overall (58/100 vs 20/100), backed by strong 30.7% margins and 11.8% revenue growth. BYSI offers better value entry with a 89.1% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

BeyondSpring Inc

HEALTHCARE · BIOTECHNOLOGY · USA

BeyondSpring Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology cancer therapies. The company is headquartered in New York, New York.

Vertex Pharmaceuticals Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.

Want to dig deeper into these stocks?